Described herein are silicone-containing acrylic polymers useful, for example, in transdermal drug delivery compositions, to methods of making and using them, to transdermal drug delivery compositions comprising them, and to methods of making and using such transdermal drug delivery compositions. The polymers are particular suitable for formulating amine drugs, such as amphetamine, methylphenidate, rivastigmine, paroxetine and clonidine.

This invention provides methods utilizing ketamine for the treatment of motor disorders and/or side effects associated with certain medications used in the treatment of motor disorders. For example, in some embodiments, methods are provided for treating side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering a dose of ketamine or a pharmaceutically acceptable salt thereof. In particular, the invention provides methods for reducing dyskinesia associated with motor disorder (e.g., Parkinson's disease) treatments, and effective doses of ketamine or a pharmaceutically acceptable salt thereof.

Compositions comprising a Teneurin C-terminal Associated Peptide—1 (TCAP-1) peptide are described with respect to methods and uses of same for preventing and/or treating post-traumatic stress disorder (“PTSD”).

The present invention provides a stock compositions comprising a combinations of terpenes, that, when used as diluents in vaporizable formulations comprising cannabinoids, confer administration of reproducible constant dose of the formulations and its components such as cannabinoids, reduce throat irritation and improve the flavor of said formulations. The invention further provides vaporizable formulations comprising defined concentrations of the diluent(s) and cannabinoids. Use of the vaporizable formulations is provided as well.

Disclosed herein are compositions and methods for attenuating stress-induced mental fatigue in subject in need thereof by administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain embodiments, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. In further embodiments, paraxanthine is present in the composition in amount from about 50 mg to about 400 mg. According to certain embodiments, fatigue attenuated by the instantly disclosed method is a result of physical stress on the subject. Physical stresses that may result in mental fatigue include, but are not limited to, periods of intense exercise.

Disclosed herein are compositions and methods for attenuating stress-induced mental fatigue in subject in need thereof by administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain embodiments, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. In further embodiments, paraxanthine is present in the composition in amount from about 50 mg to about 400 mg. According to certain embodiments, fatigue attenuated by the instantly disclosed method is a result of physical stress on the subject. Physical stresses that may result in mental fatigue include, but are not limited to, periods of intense exercise.

The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.

This invention provides a compound selected from the group consisting of L-nicotine(X.sub.1)(X.sub.2) and D-nicotine(X.sub.1) (X.sub.2), or a pharmaceutically acceptable salt thereof, wherein (i) each of X.sub.1 and X.sub.2 is independently a pharmaceutically acceptable anion or a null set; and (ii) X.sub.1 and X.sub.2 cannot both be null sets. This invention also provides related compositions, as well as methods for treating a disorder reasonably believed to be ameliorated by the administration of nicotine.

Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.

The present disclosure relates to a composition, and method thereof, which comprises tryptophan whereby 10 to 90%, preferably 20 to 80% of the tryptophan is present as free tryptophan or peptide-bound tryptophan and 10 to 90%, preferably 20 to 80% of the tryptophan is present as polypeptide-bound tryptophan.